SYMBOL:

    Up to 100 tickers separated by a space .....Watch Post-Market activities
Site Map FAQ Contact us Home Personalize
Company
Industry
Earnings
US Markets
Most Active
Portfolio
Tools
ETFs
Ratings
GTX
(NQPK:GTXO Last Sale: .0165 )
Fundamentals Charts Tech Analysis Industry Earnings
Company Profile   Details

Company Web Site
NQNM: (GTXI : $1.82) (GTXO : $.0165)
$68 million Market Cap at September 12, 2013
Employs 85.
Biomedics SubIndustry up .00% / Health Industry up .00% Today
3 N. Dunlap Street, 3rd Floor Research Report Earnings Snapshot - Last 11/10/18
Van Vleet Building Fact Sheet
Memphis, TN 38163 Financial Statements
Phone: (901) 523-9700 Peer Comparison
Annual Reports

Mitchell S. Steiner, Chmn./CEO, Marc S. Hanover, Pres./COO
Developing Acapodene for the reduction in the incidence of prostate cancer in men with precancerous prostate lesions and a Phase III clinical trial for the treatment of side effects of advanced prostate cancer therapy. IPO at $14.50 February 2, 2004. Raised $78.3 million, selling 5.4 million shares, 22% of the outstanding. Lead Manager: Goldman Sachs.
Historical Charts    Technical Analysis
No Historical Data available for GTXO
Historical Charts    Technical Analysis
No Historical Data available for GTXI

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)
Common GTXO $.0165 $ 0 $.0163 $.021 313,351 $.0061 $.069 77,436
Common GTXI $1.82 $ 0 $1.75 $1.96 1,984,535 $1.31 $7.24 36,418
Capitalization
Earnings Summary ()
*** No Earnings Available***
-10121
Common Stock $67,558

A
Google



QUICK NAVIGATION SITE SEARCH   Enter Keyword:
   
Home    Subscribe    Browser Help    Subscriber Services    B-to-B    Banks    Brokerage    Telco    Site Map    Legal    Contact/Email
Copyright © 1996 - 2024 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex